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Only a small percentage of protein kinases have
been shown to adopt a distinct inactive ATP-binding
site conformation, called the Asp-Phe-Gly-out
(DFG-out) conformation. Given the high degree of
homology within this enzyme family, we sought to
understand the basis of this disparity on a sequence
level. We identified two residue positions that sensi-
tize mitogen-activated protein kinases (MAPKs) to
inhibitors that stabilize the DFG-out inactive confor-
mation. After characterizing the structure and dy-
namics of an inhibitor-sensitive MAPK mutant, we
demonstrated the generality of this strategy by
sensitizing a kinase (apoptosis signal-regulating ki-
nase 1) not in the MAPK family to several DFG-out
stabilizing ligands, using the same residue posi-
tions. The use of specific inactive conformations
may aid the study of noncatalytic roles of protein ki-
nases, such as binding partner interactions and
scaffolding effects.
INTRODUCTION
Protein kinases represent approximately 2% of all human genes
(Manning et al., 2002a), a testament to the vast number of ki-
nase-mediated signal transduction pathways. Immunity, cell
cycle regulation, and morphogenesis are only a few of the pro-
cesses controlled by protein kinases (Manning et al., 2002b).
Aberrant kinase activity can lead to diseases, such as cancer
and inflammation (Noble et al., 2004); thus, normal cell function
is reliant on precise kinase regulation, the basis of which lies in
the interconversion between active and inactive catalytic
states.
The catalytic domains of protein kinases are composed of a
larger, mainly a helical C-terminal lobe and a smaller N-terminal
lobe composedmainly of b strands. The active site is located in a
cleft between these two lobes. A flexible polypeptide called the
activation loop resides on the outer edge of the active site and
often contains serine, threonine, or tyrosine residues that can
be phosphorylated (Canagarajah et al., 1997). Activation loop
phosphorylation often results in a dramatic increase in a kinase’s
catalytic activity (Zhang et al., 2008; Zhou and Zhang, 2002).806 Chemistry & Biology 20, 806–815, June 20, 2013 ª2013 ElsevierCatalytically active kinase conformations are highly
conserved, owing to the evolutionary pressure of functional
preservation. Inactive conformations, however, lack this pres-
sure and are more varied across the kinase family. While the
exact number of discrete inactive conformations is not known
(although believed to be limited [Jura et al., 2011]), only a few
have been observed crystallographically in multiple kinases.
Small-molecule kinase inhibitors have played a large role in
determining active-site conformational accessibility by stabiliz-
ing specific active site conformations. For example, structural
characterization of the drug imatinib bound to its target kinase
Abl (Schindler et al., 2000; Zimmermann et al., 1997) revealed
that this inhibitor stabilizes a specific inactive conformation
that is characterized by the unique orientation of the highly
conserved Asp-Phe-Gly (DFG) motif at the base of Abl’s activa-
tion loop. In Abl’s active conformation (DFG-in), the aspartate
side chain of the DFG motif faces into the active site to facilitate
catalysis. Additionally, its neighboring phenylalanine residue oc-
cupies a hydrophobic pocket adjacent to the ATP-binding site. In
contrast, the activation loop of the observed inactive form (DFG-
out) undergoes a significant translocation that moves the cata-
lytic aspartate out of the active site and the phenylalanine
away from the hydrophobic pocket. Since the initial observation
that imatinib stabilizes the DFG-out conformation of Abl, a num-
ber of ATP-competitive ligands that stabilize this conformation in
other protein kinases have been identified (Davis et al., 2011; Liu
and Gray, 2006).
Although the overall topologies of kinase active sites are well
conserved across this enzyme family, less than 10% have
been observed in the DFG-out conformation (Zuccotto et al.,
2010), and most examples are tyrosine kinases (DiMauro
et al., 2006; Hodous et al., 2007; Mol et al., 2004; Schindler
et al., 2000; Wan et al., 2004), despite serine/threonine (S/T) ki-
nases constituting a majority of the human kinome (Manning
et al., 2002a). Furthermore, the few S/T kinases that have been
shown to adopt this conformation appear to be outliers in their
own subfamilies. For example, the mitogen-activated protein ki-
nase (MAPK) p38a was one of the first kinases to be character-
ized in the DFG-out conformation, and numerous structures of
this kinase bound to conformation-specific ligands that stabilize
this inactive form have been reported (Angell et al., 2008; Pargel-
lis et al., 2002). However, p38d, which is in the same MAPK sub-
family and more than 61% identical in sequence (Remy et al.,
2010), is insensitive to ligands that selectively recognize this
conformation (Sullivan et al., 2005). Furthermore, there is no
experimental evidence that other closely related MAPKs, suchLtd All rights reserved
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N-terminal kinase 3 (Jnk3), possess the ability to adopt the
DFG-out conformation (Fox et al., 1998; Xie et al., 1998; Zhang
et al., 1994).
Based on the information above, two main questions arise.
First, can p38a adopt the DFG-out inactive conformation
because of only a few sequence differences from the other
MAPKs, or is this ability due to more global determinants in ki-
nase tertiary structure? Second, how do sequence differences
contribute to ligand binding? That is, can all kinases adopt the
DFG-out inactive conformation given the appropriate ligand
and simply the energetics of known ligands that stabilize the
DFG-out conformation cause them to prefer p38a, or can p38a
access a unique conformational space that is somehow produc-
tive toward ligand binding? Unfortunately, structural studies pro-
vide no information about the dynamics or plasticity of kinases.
To wit, a reported crystal structure of the apo form of inactive
p38a adopts the DFG-in conformation (Wang et al., 1997), giving
no indication of its ability to adopt the DFG-out conformation.
Further confounding is that apo forms do exist of other kinases
in the DFG-out conformation (Griffith et al., 2004; Hubbard
et al., 1994).
Here, we report the identification of two specific residues that
allow MAPKs to adopt the DFG-out inactive conformation. We
show that mutagenesis at these positions yields kinases that
are sensitive to general ligands that stabilize this inactive confor-
mation. Additionally, we provide structural evidence that an in-
hibitor-sensitive mutant of Erk2 can adopt the DFG-out inactive
conformation. Next, using isotope-coded affinity tagging (ICAT)
experiments, we show that these mutations change the dy-
namics of the segment of the activation loop next to the DFG
motif. Finally, we extend our observations to the distantly related
yeast sterile (STE) group kinase apoptosis signal-regulating ki-
nase 1 (ASK1) to demonstrate that these two residues are rele-
vant to S/T kinases outside the MAPK family. This sensitization
strategy may be used to study the effects of inactive conforma-
tions in various noncatalytic roles of protein kinases, including
scaffolding complexes (Therrien et al., 1996) and binding partner
interactions (Rodrı´guez and Crespo, 2011).
RESULTS AND DISCUSSION
A Small-Molecule Probe Reveals Binding Preference
among MAPKs
ATP-competitive inhibitors have proven to be invaluable
reagents for studying the conformational accessibility of protein
kinase active sites. Most of these ligands, known as ‘‘type I’’ in-
hibitors, are able to bind to the active form of kinase ATP-binding
sites, where all conserved catalytic residues are in the proper
orientation for catalysis. However, a growing number of ligands
have been identified that selectively stabilize ATP-binding site
conformations that are not compatible with catalysis. These li-
gands occupy regions within the kinase that are only accessible
through the displacement of conserved catalytic residues. For
example, inhibitors that stabilize the helix aC-out inactive confor-
mation induce a rotation of helix aC that disrupts the catalytically
important salt bridge between a glutamate residue on helix aC
and a lysine residue on the N-lobe beta sheet (Krishnamurty
et al., 2013; Wood et al., 2004).Chemistry & Biology 20,Another more commonly observed inactive conformation is
the DFG-out inactive conformation described earlier. Ligands
that stabilize this conformation (type II) have substituents that
extend into a hydrophobic pocket (Figure 1A) normally occupied
by the conserved phenylalanine of the DFG motif when kinases
are in an active conformation. The translocation of the phenylal-
anine residue perturbs the position of the neighboring catalytic
aspartate of the DFGmotif. Type II ligands also contain a linkage
that connects the substituents that occupy the adenosine and
DFG-out pockets, which makes two additional hydrogen bonds
with a backbone residue in the DFGmotif (Asp) and a conserved
glutamate residue located in helix aC. Only in the DFG-out inac-
tive conformation, whereby the DFG motif phenylalanine is
removed from the DFG-out pocket, can a kinase active site
make the interactions described above with a type II inhibitor.
The reasons for the far fewer examples of S/T kinases in the
DFG-out inactive conformation, relative to tyrosine kinases, are
not known. We felt that the high sequence homology of the
MAPKs and the general availability of diverse ligands that stabi-
lize the DFG-out conformation of p38a made this kinase group
ideal for probing the sequence and structural determinants
of ATP-binding site conformational accessibility. First, we
confirmed biophysically that MAPKs other than p38a are not
sensitive to type II inhibitors, and thus are most likely unable to
adopt the DFG-out inactive conformation, with a fluorescently
labeled affinity reagent F that we have previously described (Fig-
ure 1B; Ranjitkar et al., 2010). This reagent consists of a general
ligand for the DFG-out conformation linked to a BODIPY fluoro-
phore. Upon binding to kinases that are able to adopt the DFG-
out conformation, this probe demonstrates a significant increase
in fluorescence. Direct measurement of binding affinity rather
than enzymatic inhibition allows kinase conformational accessi-
bility to be determined independent of enzyme activity or phos-
phorylation state. Because specific phosphorylation events have
been shown to affect the conformational equilibrium of some ki-
nases, this assay simplifies biochemical analysis (Seeliger et al.,
2007). The binding affinities of the unphosphorylated forms of the
MAPKs p38a, p38d, Jnk3, and Erk2 were determined for BOD-
IPY-conjugated probe F (Figure 1C; Table 1). Consistent with
previous structural studies and inhibitor screens, only p38a
bound tightly (Kd = 15 nM) to the probe.
One distinguishing characteristic of type II inhibitors is that
they display slow association and dissociation kinetics when in-
teracting with the ATP-binding sites of protein kinases (Gruen-
baum et al., 2009; Pargellis et al., 2002). This rate is slower
than that of type I inhibitors, owing to the significant conforma-
tional change that must occur in order to accommodate type II
ligands. By monitoring the loss of fluorescent signal of kinase-
bound F in the presence of a nonfluorescent competitor, the
dissociative half-life (t1/2) of p38a was determined. Probe F dis-
sociates slowly from the active site of p38a (Figure 1D; Table
1), comparable to studies with other type II ligands (Gruenbaum
et al., 2009; Pargellis et al., 2002; Sullivan et al., 2005).
Two Active Site Residues Affect MAPK Sensitivity to
Type II Inhibitors
Given that closely related kinases greatly differ in their sensitiv-
ities to a general type II ligand, we sought to determine the
sequence basis for this disparity. We confined our search to a806–815, June 20, 2013 ª2013 Elsevier Ltd All rights reserved 807
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Figure 1. A Probe for Type II Ligand Sensi-
tivity
(A) General properties of a type II ligand, which
spans a kinase active site from beyond the aden-
osine pocket through a hydrophobic pocket that
would otherwise be occupied by the DFG motif
phenylalanine.
(B) Structure of probe F.
(C) Titration of MAPKs in the presence of probe F
shows the most change in fluorescence for p38a
(blue triangles; Kd = 15 nM). Error bars indicate ±
SEM for three replicates.
(D) Active site dissociation of probe F from p38a.
The slow dissociation rate (t1/2 = 80 min) is indic-
ative of the large conformational change required
to accommodate a type II inhibitor.
(E) The hydrophobic spines of protein kinase A
(C-spine, yellow; N-spine, blue), connected by the
gatekeeper (cyan) and xDFG (green) residues
(Protein Data Bank [PDB] 1ATP).
(F) Sequence alignments of MAPK hydrophobic
spines shows that most of the residues are
conserved within the MAPK family. The gate-
keeper (cyan boxed) and xDFG (green boxed)
residues are the only positions with significant
variability.
(G) Active site dissociation of probe F from
MAPKs. A gatekeeper/xDFG double mutant of
Erk2 (Q103T/C164L, black squares) dissociates
from probe F at a similar rate to p38a (blue tri-
angles).
See also Figure S1.
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hydrophobic spines in kinases that are in the active conformation
(Kornev et al., 2006, 2008; Kornev and Taylor, 2010; Figure 1E).
While almost all of the residues in the hydrophobic spines of
p38a, p38d, Jnk3, and Erk2 are identical, one residue that con-
nects these spines is more varied (Figure 1F). This position,
known as the ‘‘gatekeeper’’ residue, blocks access to a hydro-
phobic pocket adjacent to the site of ATP binding. The gate-
keeper residue has been the subject of considerable study. A
number of drug-resistant kinase mutants with altered gate-
keeper residues have been identified in the clinic, including
breakpoint cluster region (BCR)-Abl T315I (Quinta´s-Cardama
and Cortes, 2008), epidermal growth factor receptor T790M
(Kobayashi et al., 2005), and KIT T670I (Tamborini et al., 2004).
Furthermore, conversion of the gatekeeper from a larger to a
smaller alanine or glycine residue has been used to confer sensi-
tivity to a series of orthogonal kinase inhibitors (Bishop et al.,808 Chemistry & Biology 20, 806–815, June 20, 2013 ª2013 Elsevier Ltd All rights reserved1999). Finally, a regulatory role has been
suggested for this position, based upon
the discovery of gatekeeper mutants of
Src, Abl, and Erk2 kinases that promote
autoactivation (Azam et al., 2008; Emrick
et al., 2006).
Gatekeeper mutants of p38a, p38d,
Jnk3, and Erk2 differ markedly from their
wild-type counterparts in their affinities
for fluorescent probe F (Table 1). Specif-
ically, the p38d M107T and Jnk3 M146Igatekeeper mutants exhibited low nanomolar affinities for the
probe. Conversely, the T106Q gatekeeper mutant of p38a abro-
gated binding to this probe (Kd > 1000 nM). Curiously, the Erk2
Q103T and Q103A gatekeeper mutants showed increased bind-
ing to the fluorescent probe but not to the extent demonstrated
by the p38d or Jnk3 gatekeeper mutants. Therefore, we looked
for other positions that differ between Erk2 and the other MAPKs
tested. Our attention was drawn to the residue immediately pre-
ceding the DFGmotif (xDFG), which, like the gatekeeper residue,
connects the two hydrophobic spines. The identity of this resi-
due is cysteine in Erk2 but leucine in p38a, p38d, and Jnk3.
Mutating the xDFG position to leucine (C164L) in Erk2 Q103T
and Q103A produced Erk2 variants (Q103T/C164L and Q103A/
C164L) with increased affinities for probe F (Kd = 40 nM and
13 nM, respectively). Further, probe F demonstrated slow disso-
ciative half-lives for all of these sensitized variants (Figure 1G;
Table 1). Thus, it appears that the identities of the two residues
Table 1. Binding Affinity Data of Probe F to MAPKs
Kinase Probe Kd (nM) Dissociative t1/2 (min)
p38a wild-type (WT) 15 ± 2 79.6 ± 0.2
p38a T106Q >1,000 n/d
Jnk3 WT n/ca n/d
Jnk3 M146I 10 ± 2 51.8 ± 0.2
Erk2 WT >1,000 n/d
Erk2 Q103T n/ca n/d
Erk2 Q103A n/ca n/d
Erk2 Q103T/C164L 40 ± 10 33 ± 1
Erk2 Q103A/C164L 13 ± 7 27.8 ± 1.0
p38d WT >1,000 n/d
p38d M107T 38 ± 5 26.3 ± 0.4
n/d, not determined.
aData were not convergent to a plateau and thus could not be accurately
fit to a curve.
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sensitivities to type II inhibitors and may influence their abilities
to adopt the DFG-out conformation.
Having determined MAPK residues that modulate probe F
binding, we were curious to know whether these positions
affected only the pharmacophore of this fluorescent ligand or
corresponded more broadly to other ligands that stabilize the
DFG-out inactive conformation. Therefore, we tested their enzy-
matic inhibition by a series of diverse type II ligands. In order to
do so, it was necessary to activate the MAPKs with their respec-
tive MAPK kinases (MEKs). All MAPK variants were significantly
activated by their upstream MEKs, and Michaelis constants
(Km[ATP]) of the activatedMAPKs were not dramatically different
between wild-type and mutant kinases (Table 2).
A structurally diverse panel of type II inhibitors that are potent
inhibitors of p38awith varied structures but all of the features of a
general ligand for the DFG-out conformation (Figure 2) were
tested in activity assays: Iclusig (L1) is an inhibitor of wild-type
and drug-resistant forms of the oncogenic tyrosine kinase
BCR-Abl (Huang et al., 2010). L2 is derived from a series of ami-
noquinazoline inhibitors that target the Src-family kinase LckTable 2. Inhibition Data for Kinases against Type II Inhibitors
Kinase Km(ATP) (mM)
Ki (nM)
L1
p38a WT 229 ± 16 8.1 ± 0.2
p38a T106Q >1,000b 3,700 ± 400
Erk2 WT 120 ± 10 >10,000
Erk2 Q103T 83 ± 5 >10,000
Erk2 Q103T/C164L 180 ± 20 4,200 ± 600
Erk2 Q103A/C164L 137 ± 6 1,490 ± 50
Jnk3 WT 8.3 ± 0.6 1,300 ± 300
Jnk3 M146I 66 ± 3 67 ± 3
p38d WT 91 ± 6 5,800 ± 400
p38d M107T 380 ± 40 54 ± 5
aAssay was performed with 2 nM kinase.
bRate of reaction maintained linearity as high as 1,000 mM ATP.
Chemistry & Biology 20,(DiMauro et al., 2006; Brigham et al., 2013). The ATP-competitive
pharmacophore (L3) component of fluorescent probe F was also
tested (Seeliger et al., 2009). Finally, we included a pyrazolourea
(L4) inhibitor of p38a that only occupies the hydrophobic binding
pocket created by the movement of the DFGmotif to an inactive
conformation (Dumas et al., 2000). Even with the structural diver-
sity of this ligand set, it is possible that some kinases that are
able to adopt the DFG-out conformation will not be sensitive to
these inhibitors. Consistent with the binding studies using probe
F, only p38a was potently inhibited by all of the type II inhibitors
tested (Table 2). Hence, ligands that stabilize the DFG-out inac-
tive conformation appear to be ineffective toward the other
MAPKs, despite extensive structural and sequence homology.
However, the probe-sensitized kinase mutants of p38d, Jnk3,
and Erk2 were inhibited by low nanomolar concentrations of
virtually all of the inhibitors in our panel. Thus, the gatekeeper
and xDFG positions appear to control the sensitivity of MAPKs
to pharmacophores that stabilize the DFG-out inactive
conformation.
It is important to note that alanine, glycine, and isoleucine
gatekeeper mutants of Jnk3 all have high affinities for probe F
(Figure S1A available online). An isoleucine side chain is larger
than threonine and, in fact, occupies almost the same volume
as methionine (Esque et al., 2010); therefore, the presence of a
small residue at the gatekeeper position is not mandatory for
type II inhibitor sensitivity. Nonetheless, both isoleucine and
threonine are branched at their b carbon positions, so we spec-
ulated that they may be similar enough to be equally tolerated at
the gatekeeper position in other MAPKs. Indeed, p38a T106I
binds equipotently to probe F as the wild-type (Figure S1B),
and while p38d M107I is not as sensitive to inhibitors L1–L4 as
M107T, it is notably more so than the wild-type (Figure S1C). Po-
sitional comparisons among the few S/T kinases that have been
characterized to adopt the DFG-out conformation reveal several
gatekeeper residues, including a phenylalanine in CDK6 (Fig-
ure S1D). This diversity further illustrates that threonine is not
the only gatekeeper residue that permits type II inhibitor sensi-
tivity. However, it appears that methionine and glutamine at
this position strongly disfavor type II ligand inhibition, which is
noteworthy, as these two residues combined represent almostL2 L3 L4
<2a 8.0 ± 0.4 6.4 ± 1.6
1,120 ± 20 >10,000 55 ± 4
>10,000 >10,000 >10,000
10.8 ± 0.8 310 ± 20 >10,000
4.7 ± 0.3 28.4 ± 1.7 6,600 ± 700
<2a 36 ± 4 1,100 ± 300
106 ± 9 101.6 ± 1.6 660 ± 90
1.65 ± 0.05 5.9 ± 0.5 155 ± 9
>10,000 >10,000 >10,000
3.62 ± 0.18 26 ± 2 37.5 ± 0.6
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Figure 2. Structures of L1–L4 and Probe F
Despite varied structures, all of these inhibitors
stabilize the DFG-out inactive conformation. Polar
contacts are shown with dashed lines.
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2005).
Structural Evidence for DFG-Out Conformational
Accessibility
L1–L4 are conformation-selective inhibitors, in that the ATP-
binding sites of protein kinases most likely need to adopt the
DFG-out conformation in order to accommodate these ligands.
To ensure that this is the case, we determined the crystal struc-
ture of Erk2 Q103A/C164L bound to the type II ligand L2 (Table
S1). Consistent with the increased sensitivity of this kinase
mutant to type II inhibitors, the refined structure shows that the
phenylalanine residue in the DFG motif (Phe-166) undergoes a
large translocation; displacing the catalytic Asp from an orienta-
tion that is competent for catalysis (Figure 3A). Also, as ex-
pected, L2 is buried within the ATP-binding cleft of this Erk2
mutant and makes all of the characteristic contacts of a type II
inhibitor (Figure 3B). The 2-aminoquinazoline scaffold makes
similar hydrophobic contacts as the adenine ring of ATP and
forms two hydrogen bonds with the hinge region. The 3-trifluor-
omethylphenyl moiety of L2 occupies the hydrophobic pocket
created bymovement of the DFGmotif phenylalanine side chain,
and the amide linker forms hydrogen bondswith the backbone of
Asp-165 in theDFGmotif and the side chain of Glu-69 in helix aC.
Most of the activation loop is well resolved, including the TEY
activation motif. Superimposition of this structure with that of
inactive Erk2 in the DFG-in conformation (Zhang et al., 1994)
shows a dramatic difference in activation loop configuration (Fig-
ure 3C), including a translocation of 9.9 A˚ by the DFG phenylal-
anine residue. Also of note is the position of the TEY motif: not
only are these residues on opposite sides of the active site
from those in the DFG-in conformation but Tyr-185 appears to
be involved in a pi-stacking interaction with Phe-166. Interest-
ingly, p38a bound to pyrazolourea L4 in the DFG-out conforma-
tion shows no such interaction (Figure 3D), although the similar
position of its activation loopwith that of Erk2 Q103A/C164L cor-
roborates the hypothesis made by Sullivan et al. that kinases in810 Chemistry & Biology 20, 806–815, June 20, 2013 ª2013 Elsevier Ltd All rights reservedthe DFG-out conformation cannot be
activated by their upstream kinases
because the position of their TxY motif
renders their activation loops to be inac-
cessible to MEKs (Sullivan et al., 2005).
Gatekeeper Mutations Alter the
Dynamics of the Activation Loop
Having demonstrated that inhibitor-sensi-
tive Erk2 can adopt the DFG-out inactive
conformation, we explored how this
change affects its dynamic properties.
One possibility is that type II inhibitor-
sensitized kinases can sample the same
conformational space as their wild-typecounterparts, and the introductionof gatekeeper andxDFGmuta-
tions eliminate unfavorable interactions that prevent inhibitor
binding. Alternatively, the introduced mutations could allow
p38d, Jnk3, and Erk2 to access new conformational states that
are compatiblewith favorable type II ligand binding.Normally, nu-
clearmagnetic resonance (NMR) experiments can be used to test
hypotheses about protein dynamics. However, previous reports
have shown that kinase activation loops move on an ‘‘intermedi-
ate’’ time scale, rendering them unresolvable by NMR, due to
line broadening (Langer et al., 2004; Vogtherr et al., 2006). There-
fore, we used ICAT footprinting reagents to probe the active site
dynamics of Erk2 Q103T/C164L. This mass spectrometry-based
technique measures the alkylation rates of cysteine residues to
determine their solvent exposures. ICAT footprinting is comple-
mentary to hydrogen-deuterium exchange (HX) footprinting
because, while it lacks the ability to measure dynamic changes
of the entire protein in a single experiment, it has the advantage
of resolution, since it follows specific residues rather than peptic
fragments. We mutated five individual residues in the active site
of Erk2 Q103T/C164L and compared their alkylation rates to
those of the single mutant C164L (Figure 4A). This mutant was
used as a control instead of wild-type Erk2 to allow a direct com-
parison of the contribution of the gatekeeper residue. Erk2 C164L
has no measureable affinity to probe F, making it an appropriate
wild-type substitute (data not shown).
Two of the five positions examined showed altered alkylation
rates between Erk2 C164L and Q103T/C164L (Figure 4B). Posi-
tion 82 is located close to the gatekeeper residue, meaning that
the observed rate change is likely due to local steric effects of the
mutated gatekeeper residue. However, position 172 is on the
activation loop of Erk2 and quite distant from the gatekeeper.
A rate change at this position suggests the activation loop of
the type II ligand-sensitized mutant (Q103T/C164L) can access
different states than the wild-type surrogate (C164L). It also ap-
pears that this motion is localized to the region around the DFG
motif, since no rate change was observed for positions further
along the activation loop. To validate this result, we performed
2.98
2.92
2.98
2.75
Asp165
Met106
Glu69
Leu164
Ala50
Leu154 Leu105
Ile82
Ile101
Lys112
Val37
Ile72
Leu73
Ile81
Asp109
His145
Ile163A B
C D
Figure 3. L2-Bound Erk2 Q103A/C164L
Adopts the DFG-Out Inactive Conformation
(A) Erk2 Q103A/C164L with L2 (cyan) and Phe-166
(salmon) contoured at 1.0 s. Part of the N-lobe
beta sheet is hidden for clarity.
(B) Interaction map of L2 in the active site of Erk2
Q103A/C164L. Map generated by LigPlot+ (Las-
kowski and Swindells, 2011).
(C) Superimposition of L2-bound Erk2 Q103A/
C164L (green) with apo inactive Erk2 (orange;
activation loop shown only) (PDB 1ERK) reveals a
large activation loop translocation.
(D) Superimposition of L2-bound Erk2 Q103A/
C164L (green) with L4-bound p38a (magenta;
activation loop shown only) (PDB 2BAJ). No pi-
stacking is observed between Phe-169 and Tyr-
182 in p38a.
See also Table S1.
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alent effect. These results suggest that the identity of a kinase’s
gatekeeper residue affects the conformational preference of its
activation loop in the apo form.
The rate change in position 172 between wild-type surrogate
and inhibitor-sensitive Erk2 is apparent but subtle. Molecular dy-
namics simulations on both short and long time scales have
modeled DFG-out-adopting kinases moving fully into the DFG-
out conformation within nanoseconds (Frembgen-Kesner and
Elcock, 2006; Shan et al., 2009); thus, it might be expected that
sucha large translocationwouldproduceamore significant alkyl-
ation rate difference. However, structural analysis shows that,
despite the large translocation of the activation loop between
the DFG-out and DFG-in conformations, the degree of solvent
exposure ofmost of the residues (including position 172) remains
the same. Therefore, a vastly different rate difference cannot be
expected between residues occupying similar environments.
It is also important to note that, while our data suggest that
inhibitor-sensitive Erk2 has an altered activation loop conforma-
tional preference relative to wild-type Erk2, this does not neces-
sarily mean that the DFG-out conformation of the apo form of
this enzyme is substantially populated in the absence of ligand.
Such would imply that ligands that stabilize the DFG-out confor-
mation bind via a conformational selection mechanism (Boehr
et al., 2006; Tsai et al., 1999) rather thanan induced-fitmechanism
(Koshland, 1958).While kinetics andmolecular dynamics calcula-
tions provide strong supporting evidence that type II inhibitors
bind to theATP-bindingsitesofkinasesbyaconformational selec-
tionmechanism (Shan et al., 2009),we can only conclude fromour
data that our MAPKmutants have an altered conformational pref-
erence that ismoreconducive to ligandbinding than thewild-type.Chemistry & Biology 20, 806–815, June 20, 2013In a previous study by Emrick et al.,
several mutations that were predicted to
allow increased movement of a hydro-
phobic core of residues in the active site
of Erk2, including the Q103A gatekeeper
mutant, result in increased autophos-
phorylation (Emrick et al., 2006). HX foot-
printing of one of these Erk2 mutants,
I84A, showed that a portion of the activa-tion loop had substantially increased mobility. These observa-
tions are consistent with the increased sensitivity of Erk2
Q103A/C164L to type II inhibitors. However, the dynamic differ-
ence we observed in position 172 between wild-type surrogate
and inhibitor-sensitive Erk2 did not appear in Erk2 I84A from
the HX footprinting experiment. Furthermore, liquid chromatog-
raphy/mass spectrometry (MS) data revealed that, unlike the
Q103A and Q103T single mutants, recombinant Erk2 Q103T/
C164L and Q103A/C164L expressed in E. coli were not phos-
phorylated at either residue of the TEY activation motif (Fig-
ure S2). These observations suggest that the dynamic
differences observed in our footprinting experiments are inde-
pendent of any autophosphorylation capability and thus need
not be consistent with the HX study by Emrick et al. Furthermore,
the I84A mutant, previously shown to undergo a high rate of
autophosphorylation (Emrick et al., 2006), showed negligible
binding to our fluorescent probe (data not shown), refuting the
possibility that autophosphorylation capability and DFG-out
conformational accessibility are correlated. Interestingly, the
I84A/C164Lmutant showed very little autophosphorylation, sug-
gesting that position 164 is a general switch that downregulates
autophosphorylation.
To our knowledge, the only study to examine the xDFG posi-
tion was by Martin et al., who targeted this residue in the devel-
opment of new type II inhibitors for Aurora A kinase (Martin et al.,
2012). However, the DFG motif itself has been studied intensely.
The catalytic aspartate of this motif makes critical polar contacts
with type II inhibitors; thus, it is reasonable that a large adjacent
residue may hinder its ability to make these contacts. However,
in the case of the Erk2 Q103T/C164L double mutant, leucine is
considered to be larger in size (Esque et al., 2010) and similarª2013 Elsevier Ltd All rights reserved 811
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Figure 4. ICAT Footprinting of Inhibitor-Sensitive and Inhibitor-
Insensitive Erk2
(A) Residue positions studied (black sticks). The hinge region (yellow), acti-
vation loop (cyan), DFG motif (magenta sticks), and gatekeeper residue
(spheres) are also shown (PDB 1ERK).
(B) Footprinting time courses. The proximity of position 82 to the gatekeeper
provides the explanation that a smaller gatekeeper residue, as in the case of
Erk2 Q103T/C164L, would provide greater solvent accessibility and a faster
alkylation rate. Position 172, however, is far from the gatekeeper and still
shows altered rates for both Erk Q103T/C164L and Q103A/C164L. Error bars
indicate ± SEM for three replicates.
See also Figures S2 and S3.
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cysteine. Furthermore, we found thatmutating the xDFGposition
from leucine to cysteine in the inhibitor-sensitive Jnk3 M146I
mutant abolishes binding to probe F (Figure S3A). Therefore, in
conjunction with the gatekeeper residue, this position appears
to play a role in the DFG-out conformational accessibility of pro-
tein kinases.
The Gatekeeper and xDFG Mutations Are General
In a recent proteomic screen using a type II inhibitor to identify
kinases that can adopt the DFG-out conformation, we identified812 Chemistry & Biology 20, 806–815, June 20, 2013 ª2013 Elsevierthe S/T kinase Stk10 (LOK) (Ranjitkar et al., 2010). Stk10 resides
in the STE kinase group, whose human members are homolo-
gous to yeast Ste20 kinase (Record et al., 2010) but share little
sequence similarity to MAPKs (Figure 5A). Enrichment of Stk10
with resin-coupled L3 and nanomolar affinity of purified recombi-
nant kinase to BODIPY-conjugated probe F corroborated this
result. Furthermore, we found that Stk10 was sensitive to the
panel of type II inhibitors described above (Figure 5C). Finally,
a crystal structure was recently solved of Stk10 in the DFG-out
inactive conformation (Ranjitkar et al., 2012; Figure 5B), making
it one of only a handful of S/T kinases outside the MAPK family to
be structurally characterized in this form.
To test whether our observations for MAPKs are general, we
turned to another kinase in the STE group, ASK1. Unlike Stk10,
this closely related kinase showed no measureable binding to
our BODIPY-labeled inhibitor or enzymatic inhibition by any of
the type II inhibitors in our panel (Figure 5C). Therefore, ASK1
provided an ideal candidate to test the generality of using the
gatekeeper and xDFG positions to alter DFG-out conformational
accessibility. Mutating the gatekeeper position of ASK1 from a
methionine to a threonine residue generated an ASK1 mutant
(M754T) that has a dissociation constant of 1.3 mM for probe F
(Figure S3B). Encouraged by this result, we also mutated the
xDFG position and found that the M754T/S821C double mutant
bound to this probewith a Kd of 50 nM (Figure 5C). Enzymatic ac-
tivity assays using this mutant showed that almost all of the small
molecules in our type II panel exhibited nanomolar inhibition of
this kinase. These data strongly suggest the generality of the
gatekeeper and xDFG positions as mediators of the DFG-out
inactive conformation.
SIGNIFICANCE
More than 10 years after its discovery, the DFG-out inactive
conformation appears to be accessible by only a handful of
protein kinases. Given the significant interest in exploiting
the hydrophobic pocket exposed in this conformation to
gain a selectivity advantage, it is a worthwhile endeavor to
determine if the DFG-out conformation is accessible to all
kinases given the proper inhibitor or if the accessibility of
this conformation is limited by the dynamic properties of
the kinase itself. However, such studies are difficult to con-
trol, due to the often significant sequence disparity between
protein kinases.
We have demonstrated that two residue positions in
the active site of protein kinases appear to modulate their
sensitivity to inhibitors that stabilize the DFG-out inactive
conformation. Specifically, we showed that mutations at
these positions conferred the ability to adopt the DFG-out
conformational state that was disfavored in the wild-type ki-
nase. This effect was demonstrated for the MAPK family as
well as the distantly related STE kinase family, suggesting a
general trend across many protein kinases.
Our footprinting experiments suggest that the dynamics
of kinases that can adopt the DFG-out conformation are
different from those that cannot. However, more research
is required to fully discern the dynamic nature of these
kinases. Concurrently, our strategy may be used to
rapidly sensitize kinases to type II ligands and studyLtd All rights reserved
Ponatinib GP17 DSA7 Pyrazolourea Probe Kd (nM) Diss. t1/2 (min)
Stk10 10.0 ± 0.5 22 ± 1 8 ± 1 210 ± 20 30 ± 8 68 ± 1
ASK1 wt >10,000 >10,000 >10,000 n/d >2,000 n/d
ASK1 M754T/S821C 27 ± 2 7.7 ± 0.4 116 ± 5 n/d 50 ± 10 30 ± 1
STE
Group
CMGC
group
A
C
B
IC50 (nM)
Figure 5. The Gatekeeper/xDFG Sensitiza-
tion Strategy Is General
(A) Kinome dendrogram with the S/T kinases p38a
(black) and Stk10 (red) circled illustrates the
distant relationship between the two kinases. Ki-
nome illustration reproduced courtesy of Cell
Signaling Technology (http://www.cellsignal.com).
(B) Stk10 bound to L3 (magenta) in the DFG-out
conformation with activation loop (yellow; F176 in
sticks) highlighted (PDB 4EQU).
(C) Inhibition data of STE group kinases against
inhibitors L1–L4 and binding and dissociation data
of probe F. The ASK1 gatekeeper/xDFG double
mutant (M754T/S821C) is inhibited at nanomolar
levels for all inhibitors tested and binds to probe F
with nanomolar affinity. n/d, not determined.
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EXPERIMENTAL PROCEDURES
Cloning
Genes for mouse p38a, human ASK1, and human Stk10 (S. Knapp) were pro-
vided in bacterial expression vectors. Genes for human Jnk3, mouse p38d (R.
Davis), and rat Erk2 (J. Blenis) were cloned into His6 vector pMCSG7 (M. Don-
nelly). Genes for human MEK6, human MEK4, humanMEK7 (R. Davis), human
MEK2 (P. Khavari), and human Map3k1 (G. Johnson) were cloned into His6-
glutathione S-transferase (GST) vector pMCSG10 (M. Donnelly). Mutagenesis
was performed by Quikchange (Agilent). Plasmids were isolated from cultures
grown from single colonies and sequenced. Primers used for cloning and
mutagenesis are available upon request.
Protein Expression and Purification
Detailed procedures are in the Supplemental Information.
Small Molecule Synthesis
Detailed procedures and commercial suppliers are in the Supplemental
Information.
Fluorescent Probe Measurements
These experiments were performed as described (Hari et al., 2012; Ranjitkar
et al., 2010).
Kinase Activation and Activity Assays
ASK1 and Stk10 were catalytically active after purification. MAPKs were acti-
vated as follows prior to use in activity assays: kinase was incubated in phos-
phorylation buffer (50 mM 3-(N-morpholino)propanesulfonic acid [pH 7.4],
10 mM MgCl2, 1 mM dithiothreitol [DTT], 0.001% [v/v] Tween 20) with BSA
(0.1 mg/ml), ATP (1.3 mM), and upstream kinase (MEK6 for p38a and -d,
MEK2 for Erk2, and Map3k1+MEK4+MEK7 for Jnk3) for 1 hr at room
temperature.
Activated kinase was incubated with inhibitor (4% in DMSO, 10 mM
starting concentration, then 3-fold dilutions to 0.5 nM) in kinase reaction buffer
(50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [pH 7.5], 60 mM
MgCl2, 1 mM EGTA) with BSA (50 mg/ml), myelin basic protein (0.2 mg/ml), so-
dium orthovanadate (2 mM), cold ATP (13 mM), and g32P ATP (PerkinElmer)
(0.2 mCi/well) and spotted onto a phosphocellulose membrane (Whatman).
Enzyme concentrations and incubation times varied by kinase based on
enzyme linearity. The membrane was washed four times with 0.05% phos-Chemistry & Biology 20, 806–815, June 20, 2013phoric acid, dried, and exposed overnight to a
phosphor screen (GE Healthcare). The screen
was then scanned by a phosphor scanner, and
spots were quantitated using ImageQuant soft-ware. Ki values were determined by nonlinear regression using Graphpad
Prism software.
Kinetics
Erk2 wild-type, Q103T/C164L, and Q103A/C164L were coexpressed with
constitutively active GST-MEK2 and purified as above to yield activated,
ATP-free kinase. Other kinases were expressed, purified, and activated as
above but then desalted using Zeba spin columns (Pierce) to remove ATP. Ac-
tivity assays were performed as described above but with different concentra-
tions of ATP (typically 1.6 mM cold ATP with 3.2 mCi g32P ATP starting concen-
trations, then 2-fold dilutions to 12.5 mM cold ATP with 25 nCi g32P ATP). Km
values were determined by nonlinear regression using Graphpad Prism
software.
Mass Spectrometry
Kinases (75 pmol) were precipitated with 0.02% sodium deoxycholate and
10% trichloroacetic acid on ice for 10 min. The mixture was centrifuged at
4C for 15 min, and the pellet was washed with cold acetone. After centri-
fugation, the pellet was resuspended in 30 ml of 200 mM Tris (pH 8.0),
8 M urea, and 2.4 mM iodoacetamide, and incubated in the dark for
30 min. The solution was then diluted with 210 ml 200 mM Tris (pH 8.0),
5.7 mM CaCl2, and 1 mg/ml porcine trypsin (L-(tosylamido-2-phenyl) ethyl
chloromethyl ketone treated, Sigma) and incubated at 37C overnight.
Sample (0.3 pmol) was injected onto a Thermo Scientific Dionex Acclaim
Pepmap100 NanoLC capillary column (C18, 150 mm length, infective dose
75 mm, 3 mm particle size) connected inline to a Finnigan liquid chromatog-
raphy quadrupole mass spectrometer. Peptides of interest were identified by
MS/MS data (Sequest), and corresponding extracted ion chromatograph
peaks were integrated.
ICAT Footprinting
Positions chosen for study were mutated to cysteine using site-directed muta-
genesis. Kinases were purified as described above but desalted into 50 mM
Tris pH 8.0, 50 mM KCl, 5 mM MgCl2, and 0.5 mM Tris(2-carboxyethyl)phos-
phine hydrochloride. Heavy labeling reagent was added to protein solutions
(3 mM), and aliquots were taken at specified times and quenched with excess
DTT. Samples were then prepared and analyzed by mass spectrometry as
described above, except light labeling reagent was used instead of iodoaceta-
mide. Alkylation curves were fit using GraphPad Prism software.
Crystallography
Detailed procedures are in the Supplemental Information.ª2013 Elsevier Ltd All rights reserved 813
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The Protein Data Bank accession number for the inhibitor-bound Erk2 Q103A/
C164L structure reported in this paper is 4I5H.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2013.05.005.
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